Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

15.97
+0.57003.70%
Post-market: 16.000.0300+0.19%19:30 EDT
Volume:3.49M
Turnover:55.51M
Market Cap:2.98B
PE:-4.77
High:16.12
Open:15.40
Low:15.25
Close:15.40
52wk High:27.31
52wk Low:12.77
Shares:186.58M
Float Shares:186.00M
Volume Ratio:0.91
T/O Rate:1.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:4.24
PE(LYR):-4.60

Loading ...

RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Sep 09

U.S. Research Roundup-Argan, Mastec, Oracle

Reuters
·
Sep 09

Dyne Therapeutics, Inc. : Raymond James Cuts Target Price to $37 from $40

THOMSON REUTERS
·
Sep 09

Dyne Therapeutics, Inc. : JP Morgan Cuts to Underweight from Neutral

THOMSON REUTERS
·
Sep 09

Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan

TIPRANKS
·
Sep 09

Small U.S. Stocks Close Lower; Dyne Therapeutics Posts Biggest Loss

Dow Jones
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Dyne Therapeutics falls -22.3%

TIPRANKS
·
Sep 08

Dyne Therapeutics Set for Biggest Single-Day Drop Since Jan 2025; Last Down 22%

THOMSON REUTERS
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Sarepta Therapeutics Down 11.4%, Dyne Therapeutics Down 22%

THOMSON REUTERS
·
Sep 08

Top Premarket Decliners

MT Newswires Live
·
Sep 08

Dyne Therapeutics to Present One-Year Phase 1/2 Achieve Data for DM1 Drug DYNE-101 at Upcoming Meetings

Reuters
·
Sep 08

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 Achieve Trial of Z-Basivarsen (Dyne-101) for Myotonic Dystrophy Type 1 (Dm1) at Upcoming Medical Meetings

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 08

Sarepta, Dyne Sink After Novartis Muscle Disorder Trial Failure

Reuters
·
Sep 08

Sarepta Therapeutics Down 15.6%, Dyne Therapeutics Down 29%

THOMSON REUTERS
·
Sep 08

Shares of Some Drug Developers Fall Premarket After Novartis Late-Stage Muscle Disorder Trial Fails

THOMSON REUTERS
·
Sep 08

Novartis Twin Drug Setbacks Pile Pressure on Pipeline, CEO

Reuters
·
Sep 08

Dyne Therapeutics Advances Four DMD Exon-Skipping Candidates into IND-Enabling Studies

Reuters
·
Sep 03